64 results
8-K
EX-10.1
INM
InMed Pharmaceuticals Inc
9 Feb 24
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
12:34pm
of physical or mental illness or injury and where it would cause undue hardship to the Company to accommodate.
(iv)
“Good Reason” means the occurrence
8-K
EX-10.2
INM
InMed Pharmaceuticals Inc
13 Dec 22
InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor
3:47pm
that if the Consultant breaches any of the Consultant’s obligations under this Agreement, that breach may give rise to irreparable injury
8-K
EX-10.1
3g7hsnfmolbdcj3
19 Jul 22
InMed Announces Appointment of Chief Operating Officer
7:43pm
424B5
55fjpbkp97c
3 Jun 22
Prospectus supplement for primary offering
9:45pm
424B3
17afx oxt6rpz
25 Apr 22
Prospectus supplement
5:02pm
424B3
3e5w fcreul
7 Apr 22
Prospectus supplement
4:46pm
S-3
aqolsh 22em2e1i
4 Feb 22
Shelf registration
4:36pm
8-K/A
EX-99.1
66wgrqsi4w3nq rbd
22 Dec 21
Audited Financial Statements
12:00am
8-K/A
EX-99.2
rcs3jbj 8qt
22 Dec 21
Audited Financial Statements
12:00am
8-K
EX-2.1
uhi8 fsnjn9uw
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm
8-K
EX-99.1
05auosd8p81q e1
30 Sep 21
Regulation FD Disclosure
1:30pm
10-K
EX-2.1
e03sg9vrlcm7
24 Sep 21
Annual report
7:31am
10-K
uprnzql6
24 Sep 21
Annual report
7:31am
424B3
7yhyp2n48r kozc6yodz
22 Jul 21
Prospectus supplement
10:27am